Developer docs
API playgroundTry for free, no card

Search company profiles

Varda

Full company profile

uuid00002xf

Namestring
Varda
Legal namestring
Varda Space Industries, Inc
Websiteurl
varda.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Varda Space Industries is a microgravity-enabled life sciences and aerospace company that operates the W-Series — the first commercial free-flying orbital production satellite and reentry vehicle platform — to process materials in low-Earth orbit and return them to Earth. The company was founded in 2021 in El Segundo, California, and serves three primary customer segments: pharmaceutical and biopharma companies (e.g., United Therapeutics, Improved Pharma, SSPC) seeking improved crystal forms and formulations; U.S. government defense and civilian agencies (U.S. Air Force Research Laboratory, U.S. Navy, NASA, Sandia National Laboratory, Department of War) using the platform as a routine, recoverable hypersonic testbed; and a third emerging vertical of advanced materials and semiconductor customers (United Semiconductors). The W-Series capsule reenters at over 18,000 mph (Mach 25+), producing true hypersonic flight conditions unavailable in ground testing.

The W-Series is built end-to-end in-house at Varda's El Segundo facility, including a vertically integrated satellite bus (debuted on W-4/W-5) and a NASA-Ames-licensed C-PICA ablative heatshield manufactured by Varda. Payload capacity exceeds 100W of power and tens of kilograms of internal mass, with configurable thermal protection and mission profiles. A terrestrial Hypergravity Crystallization Screening Platform serves as a pre-flight screening module for biopharma customers, and peer-reviewed publications in Nature Partner Journals Microgravity, Crystal Growth & Design, and Acta Crystallographica document work on ritonavir (Form III, Form IV) and nirmatrelvir. The company has completed six W-series missions (W-1 through W-6) between February 2024 and May 2026, with four capsules recovered at Australia's Koonibba Test Range under a Southern Launch partnership covering 20 reentries through 2028.

Varda's revenue model combines fixed-cost government reentry service contracts (e.g., the $48 million AFRL contract awarded in December 2024, the Department of War MACH-TB 2.0 program), professional-services style pharmaceutical formulation contracts (United Therapeutics is paying Varda to identify new polymorphs of existing drugs, with first trial targeted for 2027), and joint development/payload-hosting agreements (United Semiconductors multi-flight JDA). Go-to-market is direct enterprise field sales with dedicated email funnels for government (testbed@varda.com) and biopharma (pharma@varda.com) buyers. Channel partners include SpaceX for Falcon 9 rideshare launches, Rocket Lab for Pioneer spacecraft buses under a four-vehicle build contract, and Southern Launch for Australian reentry operations. As of early 2026 the company had raised approximately $329 million in venture capital (with an additional ~$275M round closed in February 2026) at a reported $1.6 billion valuation, employs 101–250 people, and operates from El Segundo with a Washington, D.C. government-relations office.

Short descriptiontext

Varda Space Industries operates the W-Series platform, the first commercial free-flying orbital production satellite and reentry vehicle, to process pharmaceutical, semiconductor, and advanced materials in microgravity and return them to Earth for biopharma companies, U.S. defense and civilian agencies, and materials researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersEl Segundo, United States
HQ citystring
El Segundo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orbital manufacturing services, space reentry vehicles, microgravity crystallization platform, hypersonic testbed services, pharmaceutical space research
Industry5 codes
PRIMARYIMABACAB
Spacecraft & Satellites (Civil/Commercial)
SECONDARYIMABACAG
Guidance, Navigation & Control (GNC) for Space Systems
SECONDARYIMABACAK
Spacecraft Integration, Assembly & Test (IAT)
SECONDARYIMABACAF
Space Structures, Mechanisms & Thermal Control
SECONDARYIMABACAM
Space Logistics & In-Orbit Servicing (Refueling, Tug, Debris Removal)
NAICS code3 codes
  • Guided Missile and Space Vehicle Manufacturing336414
  • Other Guided Missile and Space Vehicle Parts and Auxiliary Equipment Manufacturing336419
  • Guided Missile and Space Vehicle Propulsion Unit and Propulsion Unit Parts Manufacturing336415
SIC code3 codes
  • Guided Missiles & Space Vehicles & Parts3760
  • Aircraft & Parts3720
  • Aircraft3721
Product category
Space Manufacturing Services
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Service Contracts
TypeProfessional Services
Description

Varda is paid by pharmaceutical companies to conduct microgravity crystallization experiments in orbit and return the resulting materials for analysis. United Therapeutics is paying Varda to identify new crystal forms (polymorphs) of existing drugs. First formulations scheduled to fly on upcoming W-series missions.

spacenews.com
2Government Reentry Vehicle Operations (Fixed-Cost)
TypeManaged Services
Description

Varda provides fixed-cost, routine reentry to government customers (U.S. Air Force, U.S. Navy, NASA) for hypersonic test bed missions. Each mission costs less than a representative test vehicle. Funded through programs like the Air Force Research Laboratory's Prometheus program. AFRL awarded $48 million to test payloads on reentry capsules.

varda.com
3Joint Development and Payload Hosting Agreements
TypeLicensing Royalties
Description

Multi-flight joint development agreements with research partners (e.g., United Semiconductors) for orbital manufacturing of crystals. Varda accommodates payloads from outside customers and academic researchers on its W-series vehicles for material processing in microgravity.

varda.com
4Defense Contract Revenue (MACH-TB 2.0)
TypeManaged Services
Description

Department of War selected Varda (alongside Stratolaunch) to support Task Area 3 of the MACH-TB 2.0 hypersonic test bed program, focusing on reusable, recoverable flight test solutions to support Pentagon's goal of 50 hypersonic flight tests per year.

executivegov.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
Pricing details2 tiers
1Quote-based enterprise engagement for government and biopharma customers
ModelOther
Notes

Pricing not publicly listed; customers engage via dedicated email channels and request demos/contact via the website.

varda.com
2Fixed-cost mission-based pricing for reentry services
ModelUnit Pricing
Notes

W-5 mission described as providing 'fixed-cost, routine reentry' offering a 'unique, cost-effective platform for iterative testing of hypersonic flight characteristics.' Lowest cost, most rapid, recoverable option for hypersonic testbed.

varda.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Varda builds and operates the W-Series, the first commercial free-flying orbital production satellite and reentry vehicle, manufactured end-to-end in-house at its El Segundo facility. The platform processes materials in microgravity (primarily pharmaceuticals and advanced materials) and returns them to Earth via ablative heatshield-equipped capsules that reenter at over 18,000 mph. Varda sells this capability as three vertical solutions: biopharma microgravity formulation services, a government hypersonic testbed, and a microgravity research platform for commercial and academic customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • W-series reentry vehicle hits Mach 25+ on every mission, experiencing 300W/cm² heat flux and 18,000K+ in the flow field
+4 more records
Product overview1 text field

Varda offers a unified orbital platform-plus-modules architecture centered on the W-Series, the first-ever commercial free-flying satellite and reentry vehicle built specifically for the return of materials from orbit. The W-Series platform — built end-to-end in-house at Varda's El Segundo facility — supports three vertical solutions: the Biopharma Microgravity Formulation Platform (for pharmaceutical crystallization and formulation in microgravity), the Hypersonic Testbed for Government (a Mach 25+ reusable reentry testbed for defense and aerospace customers), and the Microgravity Research Platform (for crystal growth, advanced materials, and biomedical research). Core platform components include the C-PICA heatshield (NASA-licensed, manufactured by Varda) and Varda's vertically integrated satellite bus. The terrestrial Hypergravity Crystallization Screening Platform serves as a pre-flight add-on module to derisk pharmaceutical compounds before microgravity missions. Each W-Series mission flies multiple customer payloads and supports government-funded hypersonic research (e.g., AFRL Prometheus program, NASA payloads) alongside commercial pharmaceutical processing, with routine reentry at the Koonibba Test Range in South Australia (via the Varda-Southern Launch partnership through 2028) and historical landing at the Utah Test and Training Range.

Product and service4 records
1W-Series Orbital Production and Reentry Platform
CategoryCore Platform
Description

Varda's flagship free-flying orbital production satellite and reentry vehicle platform, built end-to-end in-house at the El Segundo facility. The W-Series is the first commercial satellite and reentry vehicle built specifically for the return of materials from orbit, with capsules that enter Earth's atmosphere at more than 18,000 miles per hour (Mach 25+) and land via parachute. It supports three vertical solutions (Biopharma, Government, Microgravity Research) on each mission.

2Biopharma Microgravity Formulation Platform
CategorySolution / Vertical Product
Description

Microgravity-enabled pharmaceutical development platform for small molecules and biologics sold to pharmaceutical and biopharma customers. Microgravity suppresses convective currents, buoyancy, and sedimentation to produce more uniform crystals, improving shelf-life, bioavailability, and patient experience. Supports particle size tuning and formation of large ordered crystals for X-ray structural determination or small uniform particles for drug delivery. Structured sales funnel: terrestrial process development, hypergravity screening, in-orbit process development with material return, and comprehensive analysis.

3Hypersonic Testbed for Government
CategorySolution / Vertical Product
Description

Off-the-shelf reusable hypersonic testbed that reproduces high-hypersonic and reentry flight environments (Mach 25+, 18,000 mph, 300W/cm² heat flux, 18,000K+ flow field) at lower cost than dedicated test vehicles. Configurable payload capacity (over 100W power, tens of kilograms internal mass) supports testing of thermal protection materials, navigation, communication, and sensors for U.S. Air Force, U.S. Navy, NASA, and national laboratory customers.

4Microgravity Research Platform
CategorySolution / Vertical Product
Description

Free-flying orbital research service for crystal growth, advanced manufacturing and materials, and biomedical research. Researchers design experiments for orbit with autonomous operation and payload return to Earth on a predictable timeline, supporting repeatable flight iteration as an alternative to ISS-based or crewed-station platforms during the ISS transition.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Build partner (Pioneer spacecraft bus) and adjacent space systems provider. Operates its own launch and spacecraft business with growing in-space services ambitions, making it a broad incumbent overlap on small-satellite reentry and manufacturing.

TypeEmerging player
Description

Building commercial LEO destinations and offering microgravity R&D services for pharma/biotech. As an alternative platform to Varda's free-flying capsules, Axiom competes for the same biopharma research wallet.

TypeEmerging player
Description

Dream Chaser spaceplane offers a reusable, runway-landing alternative to capsule-based reentry for cargo return. Competes for the same biopharma and government return-logistics market with a different architectural approach.

4SpaceX
TypeBroad incumbent
Description

Launch provider for all Varda missions and a broad incumbent with reusable Dragon capsules that return cargo from orbit. Sets the launch pricing/cadence backdrop Varda depends on and competes for reentry business at the largest scale.

TypeOthers
Description

Provider of hypersonic and aerospace ground testing, including wind tunnels. Represents an alternative approach to hypersonic testing that competes for government R&D budget alongside Varda's flight-test model.

TypeEmerging player
Description

Provides orbital transfer and hosted payload services. While focused on in-space transportation rather than reentry, Momentus operates in the same small-satellite services layer and could expand into return logistics.

TypeDirect peer
Description

Direct peer in in-space manufacturing and microgravity services. Through its acquisition of Made In Space, Redwire operates space-based 3D printing and biotech research, comparable to Varda's orbital crystallization focus.

TypeEmerging player
Description

Developing a commercial space station (Starlab) with Airbus and others to succeed the ISS for microgravity research. Represents an alternative platform model for in-orbit experimentation that could compete for biopharma demand.

TypeDirect peer
Description

Direct competitor in commercial hypersonic and reentry test beds. Selected alongside Varda for the MACH-TB 2.0 Task Area 3 program to provide reusable, recoverable flight test solutions for the Pentagon.

TypeBroad incumbent
Description

Operates Cygnus cargo missions and historically developed reentry-capable vehicles. A broad incumbent in space logistics and defense, with potential to enter the recoverable test bed market that Varda currently dominates.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors38 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Varda

Space Manufacturing Servicesvarda.com

Varda Space Industries operates the W-Series platform, the first commercial free-flying orbital production satellite and reentry vehicle, to process pharmaceutical, semiconductor, and advanced materials in microgravity and return them to Earth for biopharma companies, U.S. defense and civilian agencies, and materials researchers.

What Varda does

Varda Space Industries is a microgravity-enabled life sciences and aerospace company that operates the W-Series — the first commercial free-flying orbital production satellite and reentry vehicle platform — to process materials in low-Earth orbit and return them to Earth. The company was founded in 2021 in El Segundo, California, and serves three primary customer segments: pharmaceutical and biopharma companies (e.g., United Therapeutics, Improved Pharma, SSPC) seeking improved crystal forms and formulations; U.S. government defense and civilian agencies (U.S. Air Force Research Laboratory, U.S. Navy, NASA, Sandia National Laboratory, Department of War) using the platform as a routine, recoverable hypersonic testbed; and a third emerging vertical of advanced materials and semiconductor customers (United Semiconductors). The W-Series capsule reenters at over 18,000 mph (Mach 25+), producing true hypersonic flight conditions unavailable in ground testing.

The W-Series is built end-to-end in-house at Varda's El Segundo facility, including a vertically integrated satellite bus (debuted on W-4/W-5) and a NASA-Ames-licensed C-PICA ablative heatshield manufactured by Varda. Payload capacity exceeds 100W of power and tens of kilograms of internal mass, with configurable thermal protection and mission profiles. A terrestrial Hypergravity Crystallization Screening Platform serves as a pre-flight screening module for biopharma customers, and peer-reviewed publications in Nature Partner Journals Microgravity, Crystal Growth & Design, and Acta Crystallographica document work on ritonavir (Form III, Form IV) and nirmatrelvir. The company has completed six W-series missions (W-1 through W-6) between February 2024 and May 2026, with four capsules recovered at Australia's Koonibba Test Range under a Southern Launch partnership covering 20 reentries through 2028.

Varda's revenue model combines fixed-cost government reentry service contracts (e.g., the $48 million AFRL contract awarded in December 2024, the Department of War MACH-TB 2.0 program), professional-services style pharmaceutical formulation contracts (United Therapeutics is paying Varda to identify new polymorphs of existing drugs, with first trial targeted for 2027), and joint development/payload-hosting agreements (United Semiconductors multi-flight JDA). Go-to-market is direct enterprise field sales with dedicated email funnels for government (testbed@varda.com) and biopharma (pharma@varda.com) buyers. Channel partners include SpaceX for Falcon 9 rideshare launches, Rocket Lab for Pioneer spacecraft buses under a four-vehicle build contract, and Southern Launch for Australian reentry operations. As of early 2026 the company had raised approximately $329 million in venture capital (with an additional ~$275M round closed in February 2026) at a reported $1.6 billion valuation, employs 101–250 people, and operates from El Segundo with a Washington, D.C. government-relations office.

Varda firmographics

Firmographics
Name
Varda
Legal name
Varda Space Industries, Inc
Website
https://varda.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
251–500 employees
Short description
Varda Space Industries operates the W-Series platform, the first commercial free-flying orbital production satellite and reentry vehicle, to process pharmaceutical, semiconductor, and advanced materials in microgravity and return them to Earth for biopharma companies, U.S. defense and civilian agencies, and materials researchers.
Ownership category
akta.pro rank

Varda industry classification

Industry
Product category
Space Manufacturing Services
NAICS
Guided Missile and Space Vehicle Manufacturing (336414), Other Guided Missile and Space Vehicle Parts and Auxiliary Equipment Manufacturing (336419), Guided Missile and Space Vehicle Propulsion Unit and Propulsion Unit Parts Manufacturing (336415)
SIC
Guided Missiles & Space Vehicles & Parts (3760), Aircraft & Parts (3720), Aircraft (3721)
akta.pro industry
PRIMARYIMABACAB
Spacecraft & Satellites (Civil/Commercial)
SECONDARYIMABACAG
Guidance, Navigation & Control (GNC) for Space Systems
SECONDARYIMABACAK
Spacecraft Integration, Assembly & Test (IAT)
SECONDARYIMABACAF
Space Structures, Mechanisms & Thermal Control
SECONDARYIMABACAM
Space Logistics & In-Orbit Servicing (Refueling, Tug, Debris Removal)

Keywords

  • Orbital manufacturing services
  • Space reentry vehicles
  • Microgravity crystallization platform
  • Hypersonic testbed services
  • Pharmaceutical space research

Where Varda is headquartered

Location

Headquarters

HQ city
El Segundo
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Varda business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Service Contracts: Varda is paid by pharmaceutical companies to conduct microgravity crystallization experiments in orbit and return the resulting materials for analysis. United Therapeutics is paying Varda to identify new crystal forms (polymorphs) of existing drugs. First formulations scheduled to fly on upcoming W-series missions.
  2. Government Reentry Vehicle Operations (Fixed-Cost): Varda provides fixed-cost, routine reentry to government customers (U.S. Air Force, U.S. Navy, NASA) for hypersonic test bed missions. Each mission costs less than a representative test vehicle. Funded through programs like the Air Force Research Laboratory's Prometheus program. AFRL awarded $48 million to test payloads on reentry capsules.
  3. Joint Development and Payload Hosting Agreements: Multi-flight joint development agreements with research partners (e.g., United Semiconductors) for orbital manufacturing of crystals. Varda accommodates payloads from outside customers and academic researchers on its W-series vehicles for material processing in microgravity.
  4. Defense Contract Revenue (MACH-TB 2.0): Department of War selected Varda (alongside Stratolaunch) to support Task Area 3 of the MACH-TB 2.0 hypersonic test bed program, focusing on reusable, recoverable flight test solutions to support Pentagon's goal of 50 hypersonic flight tests per year.

Pricing tiers

ModelBillingPrice
Other—Quote-based enterprise engagement for government and biopharma customers
Unit Pricing—Fixed-cost mission-based pricing for reentry services

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Varda product offering

Product offering

Core offering

Varda builds and operates the W-Series, the first commercial free-flying orbital production satellite and reentry vehicle, manufactured end-to-end in-house at its El Segundo facility. The platform processes materials in microgravity (primarily pharmaceuticals and advanced materials) and returns them to Earth via ablative heatshield-equipped capsules that reenter at over 18,000 mph. Varda sells this capability as three vertical solutions: biopharma microgravity formulation services, a government hypersonic testbed, and a microgravity research platform for commercial and academic customers.

Product overview

Varda offers a unified orbital platform-plus-modules architecture centered on the W-Series, the first-ever commercial free-flying satellite and reentry vehicle built specifically for the return of materials from orbit. The W-Series platform — built end-to-end in-house at Varda's El Segundo facility — supports three vertical solutions: the Biopharma Microgravity Formulation Platform (for pharmaceutical crystallization and formulation in microgravity), the Hypersonic Testbed for Government (a Mach 25+ reusable reentry testbed for defense and aerospace customers), and the Microgravity Research Platform (for crystal growth, advanced materials, and biomedical research). Core platform components include the C-PICA heatshield (NASA-licensed, manufactured by Varda) and Varda's vertically integrated satellite bus. The terrestrial Hypergravity Crystallization Screening Platform serves as a pre-flight add-on module to derisk pharmaceutical compounds before microgravity missions. Each W-Series mission flies multiple customer payloads and supports government-funded hypersonic research (e.g., AFRL Prometheus program, NASA payloads) alongside commercial pharmaceutical processing, with routine reentry at the Koonibba Test Range in South Australia (via the Varda-Southern Launch partnership through 2028) and historical landing at the Utah Test and Training Range.

Differentiator

Problem solved

Functional benefit

Products and services

  • W-Series Orbital Production and Reentry Platform Varda's flagship free-flying orbital production satellite and reentry vehicle platform, built end-to-end in-house at the El Segundo facility. The W-Series is the first commercial satellite and reentry vehicle built specifically for the return of materials from orbit, with capsules that enter Earth's atmosphere at more than 18,000 miles per hour (Mach 25+) and land via parachute. It supports three vertical solutions (Biopharma, Government, Microgravity Research) on each mission.
  • Biopharma Microgravity Formulation Platform Microgravity-enabled pharmaceutical development platform for small molecules and biologics sold to pharmaceutical and biopharma customers. Microgravity suppresses convective currents, buoyancy, and sedimentation to produce more uniform crystals, improving shelf-life, bioavailability, and patient experience. Supports particle size tuning and formation of large ordered crystals for X-ray structural determination or small uniform particles for drug delivery. Structured sales funnel: terrestrial process development, hypergravity screening, in-orbit process development with material return, and comprehensive analysis.
  • Hypersonic Testbed for Government Off-the-shelf reusable hypersonic testbed that reproduces high-hypersonic and reentry flight environments (Mach 25+, 18,000 mph, 300W/cm² heat flux, 18,000K+ flow field) at lower cost than dedicated test vehicles. Configurable payload capacity (over 100W power, tens of kilograms internal mass) supports testing of thermal protection materials, navigation, communication, and sensors for U.S. Air Force, U.S. Navy, NASA, and national laboratory customers.
  • Microgravity Research Platform Free-flying orbital research service for crystal growth, advanced manufacturing and materials, and biomedical research. Researchers design experiments for orbit with autonomous operation and payload return to Earth on a predictable timeline, supporting repeatable flight iteration as an alternative to ISS-based or crewed-station platforms during the ISS transition.

Quantifiable outcome

  • W-series reentry vehicle hits Mach 25+ on every mission, experiencing 300W/cm² heat flux and 18,000K+ in the flow field
  • +4 more outcomes

Companies that use Varda

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Varda technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Varda partnerships and signals

Strategic signal

Scale indicators12 records

Recent moves8 records

Expansion highlights3 records

Varda competitors and assessment

Company assessment

Broad incumbents

  • Rocket Lab: Build partner (Pioneer spacecraft bus) and adjacent space systems provider. Operates its own launch and spacecraft business with growing in-space services ambitions, making it a broad incumbent overlap on small-satellite reentry and manufacturing.
  • SpaceX: Launch provider for all Varda missions and a broad incumbent with reusable Dragon capsules that return cargo from orbit. Sets the launch pricing/cadence backdrop Varda depends on and competes for reentry business at the largest scale.
  • Northrop Grumman: Operates Cygnus cargo missions and historically developed reentry-capable vehicles. A broad incumbent in space logistics and defense, with potential to enter the recoverable test bed market that Varda currently dominates.

Emerging players

  • Axiom Space: Building commercial LEO destinations and offering microgravity R&D services for pharma/biotech. As an alternative platform to Varda's free-flying capsules, Axiom competes for the same biopharma research wallet.
  • Sierra Space: Dream Chaser spaceplane offers a reusable, runway-landing alternative to capsule-based reentry for cargo return. Competes for the same biopharma and government return-logistics market with a different architectural approach.
  • Momentus: Provides orbital transfer and hosted payload services. While focused on in-space transportation rather than reentry, Momentus operates in the same small-satellite services layer and could expand into return logistics.
  • Voyager Space (Starlab): Developing a commercial space station (Starlab) with Airbus and others to succeed the ISS for microgravity research. Represents an alternative platform model for in-orbit experimentation that could compete for biopharma demand.

Others

  • Calspan: Provider of hypersonic and aerospace ground testing, including wind tunnels. Represents an alternative approach to hypersonic testing that competes for government R&D budget alongside Varda's flight-test model.

Direct peers

  • Redwire Corporation: Direct peer in in-space manufacturing and microgravity services. Through its acquisition of Made In Space, Redwire operates space-based 3D printing and biotech research, comparable to Varda's orbital crystallization focus.
  • Stratolaunch: Direct competitor in commercial hypersonic and reentry test beds. Selected alongside Varda for the MACH-TB 2.0 Task Area 3 program to provide reusable, recoverable flight test solutions for the Pentagon.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Varda social profiles

Digital presence

Varda compliance and trust

Trust signal

Compliance2 records

Varda financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Varda leadership team

Management profile

Number of profiles

Profiles8 records

Varda funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors38 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Varda M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Varda

What does Varda do?

Varda builds and operates the W-Series, the first commercial free-flying orbital production satellite and reentry vehicle, manufactured end-to-end in-house at its El Segundo facility. The platform processes materials in microgravity (primarily pharmaceuticals and advanced materials) and returns them to Earth via ablative heatshield-equipped capsules that reenter at over 18,000 mph. Varda sells this capability as three vertical solutions: biopharma microgravity formulation services, a government hypersonic testbed, and a microgravity research platform for commercial and academic customers.

Is Varda a public or private company?

Varda is a private company. It is classified as venture growth investor backed and is currently operating.

When was Varda founded?

Varda was founded in 2021. It employs 251 to 500 people.

Where is Varda based?

Varda is headquartered in El Segundo, United States, in the North America region.

How does Varda make money?

Four revenue lines are on record. Pharmaceutical Service Contracts are the primary driver. The others are government Reentry Vehicle Operations (Fixed-Cost), joint Development and Payload Hosting Agreements and defense Contract Revenue (MACH-TB 2.0).

Who are Varda's main competitors?

Broad incumbents on record are Rocket Lab, SpaceX and Northrop Grumman. Emerging players are Axiom Space, Sierra Space, Momentus and Voyager Space (Starlab). Calspan is listed as an others. Direct peers are Redwire Corporation and Stratolaunch.

Does Varda have an API?

No public API is recorded for Varda.

What industry is Varda in?

Varda's product category is Space Manufacturing Services. Its primary akta.pro industry code is IMABACAB, Spacecraft & Satellites (Civil/Commercial), with a secondary code of IMABACAG, Guidance, Navigation & Control (GNC) for Space Systems. Its NAICS code is 336414 and its SIC code is 3760.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireVarda's W-9 Capsule Touches Down, Completing a Historic Double HomecomingVarda Space Industries successfully reentered and recovered its W-9 capsule on Nov. 17, 2026, after 48 days in orbit, landing in South Australia. This was the second reentry this month, following W-8's return on Nov. 5, proving the company can launch and return multiple spacecraft separately. W-7 remains healthy on orbit, with updates expected in coming weeks.ExamePor que empresas farmacêuticas estão levando medicamentos contra o câncer ao espaço?Varda Space Industries is cultivating cancer drug crystals in orbit to exploit microgravity for better crystal formation. The company plans seven missions in 2027 and ten in 2028, aiming to commercialize space-based drug manufacturing. Regulatory guidance from the UK MHRA is expected this year.Nate"우주서 항암제 만든다"…美 바르다, 한 달 새 캡슐 3대 또 띄웠다 : 네이트 뉴스Varda Space Industries launched a third capsule on October 20, carrying a drug-candidate crystal grown in microgravity. The company plans to continue launching capsules to produce medicines in space and return them to Earth. It also aims to grow semiconductor crystals, but high costs remain a challenge.PR NewswireVarda's W-8 Capsule Returns Safely from Orbit as Three Vehicles Operate in SpaceVarda Space Industries successfully reentered and recovered its W-8 capsule from orbit, landing at the Koonibba Test Range after 35 days. The capsule carried payloads from commercial and government partners, including Canopy's Smart TPS-F. W-7 and W-9 remain on orbit, marking Varda's first multi-vehicle operation.PR NewswireVarda's W-8 Capsule Returns Safely from Orbit as Three Vehicles Operate in SpaceVarda Space Industries successfully reentered and recovered its W-8 capsule from orbit, landing at the Koonibba Test Range after 35 days. The capsule carried payloads from commercial and government partners, including Canopy's Smart TPS-F. W-7 and W-9 remain on orbit, marking Varda's first multi-vehicle operation.MintCancer drugs from space? Why pharma firms are looking beyond Earth to manufacture next-gen medicines | Company Business NewsPharmaceutical firms are exploring microgravity to grow better drug crystals, with Varda Space Industries launching autonomous spacecraft for in-space manufacturing. The company has placed three capsules in orbit, including experiments on growing a potential cancer drug crystal. Varda plans seven more missions in 2027 and ten in 2028.BenzingaVarda Says One Spaceflight Could Make Medicine For Millions - United Therapeutics (NASDAQ:UTHR), RedwireVarda Space Industries says a single spaceflight could produce enough drug crystals for millions of patients. The $1.6B startup grows crystals in orbit, with a 2025 study showing they can be reproduced on Earth. Its first joint mission with United Therapeutics is planned for 2027.PR NewswireVarda Space Industries Launches W-7 to Study Cancer Drug Crystallization in OrbitVarda Space Industries launched its W-7 vehicle into orbit on Oct. 20, 2026, its third launch this month. The mission will mix a PROTAC cancer drug with an active pharmaceutical ingredient to test how microgravity improves solubility. Improved crystals could enable clinical development for this class of drugs.EleconomistaMicrogravedad: Diseñar medicamentos en el espacio exterior ya no es ciencia ficción, es ciencia aplicadaMicrogravity enables unique drug research, including protein crystallization and 3D cell studies, with Varda Space Industries and United Therapeutics partnering to synthesize drugs in space. Applications include pharmaceutical crystal production, neurological disease research, and cancer therapy studies on the ISS.Space.com2 spacecraft in orbit and 8 more coming soon: Varda has big plans for in-space manufacturingVarda Space Industries is currently operating two spacecraft in orbit after launching its W-8 and W-9 vehicles on SpaceX's Transporter-18 mission in October 2026, with a third vehicle expected to launch soon. The company plans to return all three capsules to Earth before Christmas and aims to fly seven additional missions in 2027 as it transitions to a fleet-based operational model. Supported by a recent $251 million funding round, Varda is scaling its hiring and infrastructure to meet demand while preparing for potential rocket capacity shortages anticipated around 2029.